AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CSBR
  4. [8-K] Champions Oncology, Inc. Reports Material Event

[8-K] Champions Oncology, Inc. Reports Material Event

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Champions Oncology (CSBR) filed an 8-K disclosing a leadership change effective 25 Aug 2025. Director Robert Brainin, 54, will become Chief Executive Officer while retaining his board seat. Brainin brings 25+ years of life-science experience, most recently as Chief Business Officer & EVP at Veracyte, and previously held senior roles at Genuity Science, Illumina, Thermo Fisher and Life Technologies.

Key employment terms (Exhibit 10.1): $500,000 annual base salary, discretionary bonus targeted at 75% of salary, and 700,000 stock options鈥�225,000 vesting over four years and 475,000 vesting on performance milestones. No family relationships or related-party transactions were reported.

Current CEO Ronnie Morris, M.D., will move to Executive Chairman to support the transition; Chairman Joel Ackerman will resume duties as Board Director. Related press release is filed as Exhibit 99.1.

Champions Oncology (CSBR) ha presentato un modulo 8-K comunicando un cambio nella leadership con effetto dal 25 agosto 2025. Il direttore Robert Brainin, 54 anni, assumer脿 il ruolo di Amministratore Delegato mantenendo la sua posizione nel consiglio di amministrazione. Brainin vanta oltre 25 anni di esperienza nel settore delle scienze della vita, pi霉 recentemente come Chief Business Officer e EVP presso Veracyte, e ha ricoperto ruoli dirigenziali in precedenza presso Genuity Science, Illumina, Thermo Fisher e Life Technologies.

Termini chiave del contratto di lavoro (Allegato 10.1): stipendio base annuo di 500.000 dollari, bonus discrezionale con un obiettivo del 75% dello stipendio e 700.000 opzioni azionarie 鈥� 225.000 con maturazione in quattro anni e 475.000 legate al raggiungimento di obiettivi di performance. Non sono state segnalate relazioni familiari o transazioni con parti correlate.

L'attuale CEO Ronnie Morris, M.D., passer脿 al ruolo di Presidente Esecutivo per supportare la transizione; il Presidente Joel Ackerman riprender脿 le sue funzioni come membro del Consiglio di Amministrazione. Il comunicato stampa correlato 猫 disponibile come Allegato 99.1.

Champions Oncology (CSBR) present贸 un formulario 8-K informando un cambio en la direcci贸n efectivo a partir del 25 de agosto de 2025. El director Robert Brainin, de 54 a帽os, asumir谩 el cargo de Director Ejecutivo manteniendo su asiento en la junta directiva. Brainin aporta m谩s de 25 a帽os de experiencia en ciencias de la vida, recientemente como Chief Business Officer y EVP en Veracyte, y anteriormente ocup贸 cargos senior en Genuity Science, Illumina, Thermo Fisher y Life Technologies.

T茅rminos clave del empleo (Anexo 10.1): salario base anual de 500,000 d贸lares, bono discrecional con objetivo del 75% del salario y 700,000 opciones sobre acciones 鈥� 225,000 con adquisici贸n en cuatro a帽os y 475,000 condicionadas a hitos de desempe帽o. No se reportaron relaciones familiares ni transacciones con partes relacionadas.

El actual CEO Ronnie Morris, M.D., pasar谩 a ser Presidente Ejecutivo para apoyar la transici贸n; el Presidente Joel Ackerman retomar谩 sus funciones como Director del Consejo. El comunicado de prensa relacionado se presenta como Anexo 99.1.

Champions Oncology (CSBR)電� 2025雲� 8鞗� 25鞚茧秬韯� 氚滍毃霅橂姅 瓴届榿歆� 氤�瓴� 靷暛鞚� 瓿奠嫓頃橂姅 8-K 靹滊毳� 鞝滌稖頄堨姷雼堧嫟. 鞚挫偓鞚� 搿滊矂韸� 敫岆爤鞚胳澑(54靹�)鞚� 鞚挫偓須� 鞛愲Μ毳� 鞙犾頃橂┐靹� 斓滉碃瓴届榿鞛�(CEO)搿� 鞛勲獏霅╇媹雼�. 敫岆爤鞚胳澑鞚� 25雲� 鞚挫儊鞚� 靸濍獏瓿柬暀 攵勳暭 瓴诫牓鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 斓滉芳鞐愲姅 Veracyte鞐愳劀 斓滉碃靷梾毂呾瀯鞛�(CBO) 瓴� EVP搿� 攴茧頄堨溂氅�, 鞚挫爠鞐愲姅 Genuity Science, Illumina, Thermo Fisher, Life Technologies鞐愳劀 瓿犾渼歆侅潉 鞐瀯頄堨姷雼堧嫟.

欤检殧 瓿犾毄 臁瓣贝(觳秬氍胳劀 10.1): 鞐半磯 50毵� 雼煬, 鞐半磯鞚� 75%毳� 氇╉憸搿� 頃橂姅 鞛焿 氤措剤鞀�, 70毵� 欤检潣 欤检嫕 鞓奠厴 鈥� 22毵� 5觳� 欤茧姅 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅�, 47毵� 5觳� 欤茧姅 靹标臣 氇╉憸 雼劚 鞁� 氩犾姢韺呺惄雼堧嫟. 臧�臁� 甏�瓿勲倶 甏�霠� 雼轨偓鞛� 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

順� CEO鞚� 搿滊媹 氇Μ鞀� 氚曥偓電� 鞝勴櫂鞚� 歆�鞗愴晿旮� 鞙勴暣 歆戫枆 鞚橃灔(Executive Chairman)鞙茧 鞚措彊頃橂┌, 鞚橃灔鞚� 臁办棙 鞎犾护毹检潃 鞚挫偓搿滌劀鞚� 鞛勲毳� 鞛皽頃� 鞓堨爼鞛呺媹雼�. 甏�霠� 氤措弰鞛愲電� 觳秬氍胳劀 99.1搿� 鞝滌稖霅橃棃鞀惦媹雼�.

Champions Oncology (CSBR) a d茅pos茅 un formulaire 8-K annon莽ant un changement de direction effectif au 25 ao没t 2025. Le directeur Robert Brainin, 54 ans, deviendra Directeur G茅n茅ral tout en conservant son si猫ge au conseil d'administration. Brainin poss猫de plus de 25 ans d'exp茅rience dans les sciences de la vie, r茅cemment en tant que Chief Business Officer et EVP chez Veracyte, et a auparavant occup茅 des postes de direction chez Genuity Science, Illumina, Thermo Fisher et Life Technologies.

Principaux termes d'emploi (Annexe 10.1) : salaire de base annuel de 500 000 $, bonus discr茅tionnaire ciblant 75 % du salaire, et 700 000 options d'achat d'actions 鈥� 225 000 acquises sur quatre ans et 475 000 conditionn茅es 脿 des objectifs de performance. Aucune relation familiale ni transaction avec des parties li茅es n'a 茅t茅 signal茅e.

L'actuel PDG Ronnie Morris, M.D., deviendra Pr茅sident ex茅cutif pour accompagner la transition ; le Pr茅sident Joel Ackerman reprendra ses fonctions en tant que membre du conseil d'administration. Le communiqu茅 de presse associ茅 est d茅pos茅 en Annexe 99.1.

Champions Oncology (CSBR) hat einen 8-K-Bericht eingereicht, der eine F眉hrungs盲nderung mit Wirkung zum 25. August 2025 bekannt gibt. Direktor Robert Brainin, 54 Jahre alt, wird Chief Executive Officer und beh盲lt seinen Sitz im Vorstand. Brainin bringt 眉ber 25 Jahre Erfahrung im Bereich Life Sciences mit, zuletzt als Chief Business Officer & EVP bei Veracyte, zuvor hatte er leitende Positionen bei Genuity Science, Illumina, Thermo Fisher und Life Technologies inne.

Wichtige Besch盲ftigungsbedingungen (Anlage 10.1): Jahresgrundgehalt von 500.000 USD, ein leistungsabh盲ngiger Bonus mit Zielwert von 75 % des Gehalts sowie 700.000 Aktienoptionen 鈥� 225.000 mit einer Vesting-Periode von vier Jahren und 475.000, die an Leistungserfolge gebunden sind. Familienbeziehungen oder Transaktionen mit verbundenen Parteien wurden nicht gemeldet.

Der derzeitige CEO Ronnie Morris, M.D., wird zum Executive Chairman wechseln, um den 脺bergang zu unterst眉tzen; Vorsitzender Joel Ackerman wird seine Aufgaben als Vorstandsmitglied wieder aufnehmen. Die zugeh枚rige Pressemitteilung ist als Anlage 99.1 eingereicht.

Positive
  • Appointment of industry veteran Robert Brainin as CEO brings 25+ years of oncology diagnostics and genomics expertise.
  • Structured transition keeps outgoing CEO Ronnie Morris as Executive Chairman, preserving strategic continuity.
Negative
  • Grant of 700,000 stock options could dilute existing shareholders if fully vested.
  • Leadership change introduces execution risk during the handover period.

Insights

TL;DR: Routine but orderly CEO succession; governance structure preserved; compensation sizeable yet performance-weighted.

The company followed best-practice disclosure by filing the employment agreement and detailing option tranches. Retaining Morris as Executive Chairman ensures continuity and reduces strategic disruption risk. Compensation aligns cash and equity with shareholder value creation through performance-based vesting. Dilution is a consideration, but the staged vesting mitigates immediate impact. Overall, the move appears neutral from a governance risk perspective.

TL;DR: Hiring seasoned genomics executive could accelerate CSBR鈥檚 commercialization and partnering prospects, a strategically positive shift.

Brainin鈥檚 track record at Veracyte, Illumina and Thermo Fisher shows deep commercial expertise in oncology diagnostics and genomics services鈥攁reas core to Champions鈥� PDX and data-driven offerings. His network and operational know-how should enhance business development and broaden the client base. With Morris still engaged, institutional knowledge is retained. Execution will dictate value creation, but the appointment is directionally positive.

Champions Oncology (CSBR) ha presentato un modulo 8-K comunicando un cambio nella leadership con effetto dal 25 agosto 2025. Il direttore Robert Brainin, 54 anni, assumer脿 il ruolo di Amministratore Delegato mantenendo la sua posizione nel consiglio di amministrazione. Brainin vanta oltre 25 anni di esperienza nel settore delle scienze della vita, pi霉 recentemente come Chief Business Officer e EVP presso Veracyte, e ha ricoperto ruoli dirigenziali in precedenza presso Genuity Science, Illumina, Thermo Fisher e Life Technologies.

Termini chiave del contratto di lavoro (Allegato 10.1): stipendio base annuo di 500.000 dollari, bonus discrezionale con un obiettivo del 75% dello stipendio e 700.000 opzioni azionarie 鈥� 225.000 con maturazione in quattro anni e 475.000 legate al raggiungimento di obiettivi di performance. Non sono state segnalate relazioni familiari o transazioni con parti correlate.

L'attuale CEO Ronnie Morris, M.D., passer脿 al ruolo di Presidente Esecutivo per supportare la transizione; il Presidente Joel Ackerman riprender脿 le sue funzioni come membro del Consiglio di Amministrazione. Il comunicato stampa correlato 猫 disponibile come Allegato 99.1.

Champions Oncology (CSBR) present贸 un formulario 8-K informando un cambio en la direcci贸n efectivo a partir del 25 de agosto de 2025. El director Robert Brainin, de 54 a帽os, asumir谩 el cargo de Director Ejecutivo manteniendo su asiento en la junta directiva. Brainin aporta m谩s de 25 a帽os de experiencia en ciencias de la vida, recientemente como Chief Business Officer y EVP en Veracyte, y anteriormente ocup贸 cargos senior en Genuity Science, Illumina, Thermo Fisher y Life Technologies.

T茅rminos clave del empleo (Anexo 10.1): salario base anual de 500,000 d贸lares, bono discrecional con objetivo del 75% del salario y 700,000 opciones sobre acciones 鈥� 225,000 con adquisici贸n en cuatro a帽os y 475,000 condicionadas a hitos de desempe帽o. No se reportaron relaciones familiares ni transacciones con partes relacionadas.

El actual CEO Ronnie Morris, M.D., pasar谩 a ser Presidente Ejecutivo para apoyar la transici贸n; el Presidente Joel Ackerman retomar谩 sus funciones como Director del Consejo. El comunicado de prensa relacionado se presenta como Anexo 99.1.

Champions Oncology (CSBR)電� 2025雲� 8鞗� 25鞚茧秬韯� 氚滍毃霅橂姅 瓴届榿歆� 氤�瓴� 靷暛鞚� 瓿奠嫓頃橂姅 8-K 靹滊毳� 鞝滌稖頄堨姷雼堧嫟. 鞚挫偓鞚� 搿滊矂韸� 敫岆爤鞚胳澑(54靹�)鞚� 鞚挫偓須� 鞛愲Μ毳� 鞙犾頃橂┐靹� 斓滉碃瓴届榿鞛�(CEO)搿� 鞛勲獏霅╇媹雼�. 敫岆爤鞚胳澑鞚� 25雲� 鞚挫儊鞚� 靸濍獏瓿柬暀 攵勳暭 瓴诫牓鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 斓滉芳鞐愲姅 Veracyte鞐愳劀 斓滉碃靷梾毂呾瀯鞛�(CBO) 瓴� EVP搿� 攴茧頄堨溂氅�, 鞚挫爠鞐愲姅 Genuity Science, Illumina, Thermo Fisher, Life Technologies鞐愳劀 瓿犾渼歆侅潉 鞐瀯頄堨姷雼堧嫟.

欤检殧 瓿犾毄 臁瓣贝(觳秬氍胳劀 10.1): 鞐半磯 50毵� 雼煬, 鞐半磯鞚� 75%毳� 氇╉憸搿� 頃橂姅 鞛焿 氤措剤鞀�, 70毵� 欤检潣 欤检嫕 鞓奠厴 鈥� 22毵� 5觳� 欤茧姅 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅�, 47毵� 5觳� 欤茧姅 靹标臣 氇╉憸 雼劚 鞁� 氩犾姢韺呺惄雼堧嫟. 臧�臁� 甏�瓿勲倶 甏�霠� 雼轨偓鞛� 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

順� CEO鞚� 搿滊媹 氇Μ鞀� 氚曥偓電� 鞝勴櫂鞚� 歆�鞗愴晿旮� 鞙勴暣 歆戫枆 鞚橃灔(Executive Chairman)鞙茧 鞚措彊頃橂┌, 鞚橃灔鞚� 臁办棙 鞎犾护毹检潃 鞚挫偓搿滌劀鞚� 鞛勲毳� 鞛皽頃� 鞓堨爼鞛呺媹雼�. 甏�霠� 氤措弰鞛愲電� 觳秬氍胳劀 99.1搿� 鞝滌稖霅橃棃鞀惦媹雼�.

Champions Oncology (CSBR) a d茅pos茅 un formulaire 8-K annon莽ant un changement de direction effectif au 25 ao没t 2025. Le directeur Robert Brainin, 54 ans, deviendra Directeur G茅n茅ral tout en conservant son si猫ge au conseil d'administration. Brainin poss猫de plus de 25 ans d'exp茅rience dans les sciences de la vie, r茅cemment en tant que Chief Business Officer et EVP chez Veracyte, et a auparavant occup茅 des postes de direction chez Genuity Science, Illumina, Thermo Fisher et Life Technologies.

Principaux termes d'emploi (Annexe 10.1) : salaire de base annuel de 500 000 $, bonus discr茅tionnaire ciblant 75 % du salaire, et 700 000 options d'achat d'actions 鈥� 225 000 acquises sur quatre ans et 475 000 conditionn茅es 脿 des objectifs de performance. Aucune relation familiale ni transaction avec des parties li茅es n'a 茅t茅 signal茅e.

L'actuel PDG Ronnie Morris, M.D., deviendra Pr茅sident ex茅cutif pour accompagner la transition ; le Pr茅sident Joel Ackerman reprendra ses fonctions en tant que membre du conseil d'administration. Le communiqu茅 de presse associ茅 est d茅pos茅 en Annexe 99.1.

Champions Oncology (CSBR) hat einen 8-K-Bericht eingereicht, der eine F眉hrungs盲nderung mit Wirkung zum 25. August 2025 bekannt gibt. Direktor Robert Brainin, 54 Jahre alt, wird Chief Executive Officer und beh盲lt seinen Sitz im Vorstand. Brainin bringt 眉ber 25 Jahre Erfahrung im Bereich Life Sciences mit, zuletzt als Chief Business Officer & EVP bei Veracyte, zuvor hatte er leitende Positionen bei Genuity Science, Illumina, Thermo Fisher und Life Technologies inne.

Wichtige Besch盲ftigungsbedingungen (Anlage 10.1): Jahresgrundgehalt von 500.000 USD, ein leistungsabh盲ngiger Bonus mit Zielwert von 75 % des Gehalts sowie 700.000 Aktienoptionen 鈥� 225.000 mit einer Vesting-Periode von vier Jahren und 475.000, die an Leistungserfolge gebunden sind. Familienbeziehungen oder Transaktionen mit verbundenen Parteien wurden nicht gemeldet.

Der derzeitige CEO Ronnie Morris, M.D., wird zum Executive Chairman wechseln, um den 脺bergang zu unterst眉tzen; Vorsitzender Joel Ackerman wird seine Aufgaben als Vorstandsmitglied wieder aufnehmen. Die zugeh枚rige Pressemitteilung ist als Anlage 99.1 eingereicht.

0000771856false00007718562025-07-212025-07-21


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): July 21, 2025
 
CHAMPIONS ONCOLOGY, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware 001-11504 52-1401755
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification No.)
 
1 University Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of Principal Executive Offices)
 
Registrant’s telephone number, including area code: (201) 808-8400
 
N/A
(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
    

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



INFORMATION TO BE INCLUDED IN THE REPORT
 
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
On July 18, 2025, Champions Oncology, Inc. (the “Company”) announced the hiring and appointment of Robert Brainin to serve as the Company’s Chief Executive Officer, effective as of August 25, 2025.

Mr. Brainin, age 54, has served as a member of the Company's Board of Directors since February 2021 and will remain a Director following his appointment to Chief Executive Officer. He brings more than 25 years of experience in life sciences and technology. Most recently, Mr. Brainin served as Chief Business Officer and Executive Vice President at Veracyte, an oncology diagnostics company, since July 2021. From August 2017 to January 2021, he worked at Genuity Science, where he held various positions including Chief Executive Officer, Chief Operating Officer and served as a director. Before joining Genuity, he was Vice President and General Manager of Life Sciences and Applied Genomics at Illumina, and before that as a Vice President/General Manager of the Enterprise Genomics Solutions business of Thermo Fisher Scientific, Inc. He joined Thermo Fisher via its acquisition of Life Technologies, Inc. in 2014. From 2004 to 2014, Mr. Brainin served in a number of positions at Life Technologies and its predecessor, Invitrogen, predominantly leading a variety of large businesses that served customers in the academic and BioPharma segments. In all these roles, he led the expansion of the applications of technologies or genomic data to new fields to serve the needs of growing types of users. Earlier in his career, he was a management consultant at McKinsey & Co. and has served as an adjunct professor at the University of San Diego School of Law. Mr. Brainin holds an undergraduate degree in economics from Emory University and a law degree from Harvard Law School.

Mr. Brainin has entered into an Employment Agreement (attached hereto as Exhibit 10.1). Pursuant to the agreement, he will receive an annual base salary of $500,000 and will have the opportunity to earn a discretionary target incentive bonus of 75% of his base salary. He will also receive multiple equity awards, including 225,000 options to purchase the Company’s common stock, which will vest over a four-year period, and 475,000 options to purchase the Company’s common stock which will vest at varying time points and are based on varying performance criteria.

There are no family relationships between Mr. Brainin and any director or executive officer of the Company. There are no transactions between the Company and Mr. Brainin that are subject to disclosure under Item 404(a) of Regulation S-K.

Ronnie Morris, M.D., will transition to Executive Chairman of the Board on August 25, 2025, supporting the leadership transition while remaining actively involved in the Company’s strategic initiatives. Joel Ackerman, Chairman of the Board, will transition to Board Director.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01.Financial Statements and Exhibits.
 
(d)Exhibits
The following exhibits are filed herewith:
 
Exhibit No.
99.1
Press Release dated July 18, 2025
10.1
Employment Agreement between Champions Oncology, Inc. and Robert Brainin, effective as of July 16, 2025
 


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  CHAMPIONS ONCOLOGY, INC.
  (Registrant)
   
Date: July 21, 2025By:/s/ Joel Ackerman 
  Joel Ackerman 
  Chairman of the Board of Directors 
 

Source:

FAQ

When will Robert Brainin become CEO of CSBR?

He will assume the role on August 25, 2025.

What is Robert Brainin鈥檚 compensation package at Champions Oncology?

Annual salary $500,000, target bonus 75% of salary, and 700,000 stock options with time- and performance-based vesting.

What role will current CEO Ronnie Morris take after the transition?

Dr. Morris will become Executive Chairman of the Board on August 25, 2025.

Are there any related-party transactions with the new CEO?

The filing states no related-party transactions reportable under Item 404(a) of Regulation S-K.

How are the 700,000 options structured?

225,000 options vest ratably over four years; 475,000 options vest on achieving specified performance milestones.
Stock CSBR logo
Champions Oncolo

NASDAQ:CSBR

CSBR Rankings

#6145 Ranked by Market Cap
N/A Ranked by Dividends

CSBR Latest News

Jul 21, 2025
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
Jul 18, 2025
Champions Oncology Announces Appointment of New CEO
Jul 8, 2025
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Apr 28, 2025
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
Apr 24, 2025
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

CSBR Stock Data

110.20M
10.25M
25.88%
47.79%
0.84%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
BALTIMORE